

Express Mail Label No.: EV328703118US

Date of Deposit: February 26, 2004

Attorney Docket No. 22058-516 DIV CON

GI 5252A-D2-C1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: James Tobin

SERIAL NUMBER: 09/924,338

EXAMINER: Prema Mertz

FILING DATE: August 7, 2001

ART UNIT: 1646

FOR: METHOD COMPRISING THE USE OF HUMAN INTERLEUKIN-11  
RECEPTOR PROTEINS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**

**MAR 08 2004**

**TRANSMITTAL**


Transmitted herewith for filing in the present application are the following documents:

1. Response to September 26, 2003 Office Action (9 pgs);
2. Petition for a Two-Month Extension of Time (1 pg);
3. Check No. 18159 in the amount of \$420.00 to cover extension fee; and
4. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 22058-516 DIV CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

  
Ivor R. Elfin, Reg. No. 39,529  
David E. Johnson, Reg. No. 41,874  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: February 26, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: James Tobin  
SERIAL NUMBER: 09/924,338 EXAMINER: Prema Mertz  
FILING DATE: August 7, 2001 ART UNIT: 1646  
FOR: METHOD COMPRISING THE USE OF HUMAN INTERLEUKIN-11  
RECEPTOR PROTEINS

RECEIVED

MAR 08 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Response to September 26, 2003 Office Action**

In response to the Office Action mailed September 26, 2003 ("Office Action"),  
Applicants submit the following response.

**Amendments to the Claims** are reflected in the listing of claims, which begins on page 2  
of this paper.

**Remarks** begin on page 7 of this paper.